Dimension Therapeutics Inc (DMTX) Given Consensus Recommendation of “Hold” by Analysts

Dimension Therapeutics Inc (NASDAQ:DMTX) has received a consensus recommendation of “Hold” from the eight research firms that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $5.08.

A number of analysts have recently issued reports on DMTX shares. Chardan Capital reissued a “buy” rating on shares of Dimension Therapeutics in a research note on Friday, December 22nd. Citigroup raised shares of Dimension Therapeutics from a “sell” rating to a “neutral” rating and increased their price objective for the stock from $5.50 to $6.00 in a research note on Tuesday, October 3rd. Wells Fargo & Co cut shares of Dimension Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $9.00 to $6.00 in a research note on Tuesday, October 3rd. Finally, ValuEngine raised shares of Dimension Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 30th.

Shares of Dimension Therapeutics (DMTX) opened at $5.95 on Friday. Dimension Therapeutics has a twelve month low of $1.05 and a twelve month high of $6.10. The company has a market cap of $149.06 and a P/E ratio of -2.67. The company has a current ratio of 2.01, a quick ratio of 3.33 and a debt-to-equity ratio of 0.14.

Dimension Therapeutics (NASDAQ:DMTX) last announced its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.20). The firm had revenue of $4.48 million during the quarter. Dimension Therapeutics had a negative return on equity of 240.95% and a negative net margin of 378.28%. equities research analysts predict that Dimension Therapeutics will post -1.99 EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. increased its stake in shares of Dimension Therapeutics by 206.7% in the second quarter. Goldman Sachs Group Inc. now owns 80,471 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 54,231 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in Dimension Therapeutics during the third quarter valued at $600,000. Kassirer Asset Management Corp purchased a new position in Dimension Therapeutics during the third quarter valued at $952,000. Finally, K2 Principal Fund L.P. purchased a new position in Dimension Therapeutics during the third quarter valued at $960,000. 70.33% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This story was first published by Week Herald and is the sole property of of Week Herald. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://weekherald.com/2018/01/19/dimension-therapeutics-inc-dmtx-given-consensus-recommendation-of-hold-by-analysts.html.

Dimension Therapeutics Company Profile

Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).

Analyst Recommendations for Dimension Therapeutics (NASDAQ:DMTX)

Receive News & Ratings for Dimension Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply